Pilot study of intravenous glyburide in patients with a large ischemic stroke.

ABSTRACT:

Background and purpose

Preclinical and retrospective clinical data indicate that glyburide, a selective inhibitor of sulfonylurea receptor 1-transient receptor potential melastatin 4, is effective in preventing edema and improving outcome after focal ischemia. We assessed the feasibility of recruiting and treating patients with severe stroke while obtaining preliminary information on the safety and tolerability of RP-1127 (glyburide for injection).

Methods

We studied 10 patients with acute ischemic stroke, with baseline diffusion-weighted imaging lesion volumes of 82 to 210 cm3, whether treated with intravenous recombinant tissue-type plasminogen activator, age 18 to 80 years, and time to RP-1127≤10 hours.

Results

Recruitment was completed within 10 months. The mean a

SUBMITTER: Sheth KN 

PROVIDER: S-EPMC4235339 | biostudies-literature | 2014 Jan

REPOSITORIES: biostudies-literature